Croyez Bioscience

Executive Summary

Croyez Bioscience is a Taiwanese platform biotech founded in 2020 that supplies GMP-grade recombinant proteins, mRNA raw materials, and custom CRO/CDMO services for cell and gene therapy research. Operating from Taipei, the company enables discovery through pre-clinical development across oncology, immunology, and infectious disease. Its core expertise lies in in-vitro transcription, lipid nanoparticle formulation, and molecular diagnostics, emphasizing high-quality, scalable production and analytical QC. As a private company with 50–200 employees, Croyez positions itself as a reliable partner for translational projects, though financial details remain undisclosed. The global cell and gene therapy market is expanding rapidly, driving demand for specialized raw materials and contract services. Croyez’s focus on GMP-grade materials and analytical rigor positions it well to capture a share of this growth. The company’s platform model lacks a proprietary pipeline, making it reliant on service revenue and strategic collaborations. Key catalysts include potential partnerships with cell therapy developers, capacity expansions for mRNA production, and achieving ISO 13485 certification. With no disclosed funding rounds and a niche within the biotech supply chain, Croyez offers moderate conviction as a platform play in a high-growth sector.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a leading cell therapy developer60% success
• Q4 2026Expansion of GMP mRNA production capacity70% success
• Q2 2026ISO 13485 certification for quality management80% success